Business Wire · AZN · November 13, 2026

Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer

Get the app for more

Explore stock news, insights and company research.